155 related articles for article (PubMed ID: 28697193)
1. The value of
Oner AO; Budak ES; Yıldırım S; Aydın F; Sezer C
Hell J Nucl Med; 2017; 20(2):160-165. PubMed ID: 28697193
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of metabolic 18F-FDG PET/CT parameters and hematological prognostic indicators in patients with colorectal cancer.
Cengiz A; Yersal Ö; Ömürlü İK; Yürekli Y
Indian J Cancer; 2023; 60(2):224-229. PubMed ID: 37530245
[TBL] [Abstract][Full Text] [Related]
3. Correlation between PET/CT parameters and KRAS expression in colorectal cancer.
Chen SW; Chiang HC; Chen WT; Hsieh TC; Yen KY; Chiang SF; Kao CH
Clin Nucl Med; 2014 Aug; 39(8):685-9. PubMed ID: 24978328
[TBL] [Abstract][Full Text] [Related]
4. Correlation between KRAS mutation and
Cho A; Jo K; Hwang SH; Lee N; Jung M; Yun M; Hwang HS
Abdom Radiol (NY); 2017 Jun; 42(6):1621-1626. PubMed ID: 28161825
[TBL] [Abstract][Full Text] [Related]
5. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between 18F-FDG PET/CT Scans and KRAS Mutations in Metastatic Colorectal Cancer.
Kawada K; Toda K; Nakamoto Y; Iwamoto M; Hatano E; Chen F; Hasegawa S; Togashi K; Date H; Uemoto S; Sakai Y
J Nucl Med; 2015 Sep; 56(9):1322-7. PubMed ID: 26135109
[TBL] [Abstract][Full Text] [Related]
7. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by
Ikeno Y; Seo S; Iwaisako K; Yoh T; Nakamoto Y; Fuji H; Taura K; Okajima H; Kaido T; Sakaguchi S; Uemoto S
J Transl Med; 2018 Apr; 16(1):95. PubMed ID: 29642912
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Volume-Based Fluorine-18-Fluorodeoxyglucose PET/CT Parameters for Characterizing Thyroid Incidentaloma.
Shi H; Yuan Z; Yuan Z; Yang C; Zhang J; Shou Y; Zhang W; Ping Z; Gao X; Liu S
Korean J Radiol; 2018; 19(2):342-351. PubMed ID: 29520193
[TBL] [Abstract][Full Text] [Related]
9. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
10. Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.
Krikelis D; Skoura E; Kotoula V; Rondogianni P; Pianou N; Samartzis A; Xanthakis I; Fountzilas G; Datseris IE
Anticancer Res; 2014 May; 34(5):2571-9. PubMed ID: 24778079
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment tumor SUV
Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
[TBL] [Abstract][Full Text] [Related]
12. Genetic Alterations in Colorectal Cancer Have Different Patterns on 18F-FDG PET/CT.
Chen SW; Lin CY; Ho CM; Chang YS; Yang SF; Kao CH; Chang JG
Clin Nucl Med; 2015 Aug; 40(8):621-6. PubMed ID: 26018692
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
14. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
17. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
[No Abstract] [Full Text] [Related]
18. The relationship between
McSorley ST; Khor BY; Tsang K; Colville D; Han S; Horgan PG; McMillan DC
Colorectal Dis; 2018 May; 20(5):407-415. PubMed ID: 29178362
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
20. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
